Teva ' s Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale. This news comes from individuals privy to the matter, who indicated that the current healthcare asset…#api #teva #richardfrancis #ussupremecourt #gskplc #gsk
Source: Reuters: Health - Category: Consumer Health News Source Type: news